Potential Mechanism Underlying the Role of Mitochondria in Breast Cancer Drug Resistance and Its Related Treatment Prospects

Breast cancer incidence and mortality rates have been consistently high among women. The use of diverse therapeutic strategies, including chemotherapy, endocrine therapy, targeted therapy, and immunotherapy, has improved breast cancer prognosis. However, drug resistance has become a tremendous obsta...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 11; p. 629614
Main Authors Li, Yuefeng, Li, Zhian
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 18.03.2021
Subjects
breast cancer
chemoresistance
drug resistance
mitochondrial
Oncology
tumor microenvironment
breast cancer
chemoresistance
drug resistance
mitochondrial
tumor microenvironment
Online AccessGet full text

Cover

More Information
Summary:Breast cancer incidence and mortality rates have been consistently high among women. The use of diverse therapeutic strategies, including chemotherapy, endocrine therapy, targeted therapy, and immunotherapy, has improved breast cancer prognosis. However, drug resistance has become a tremendous obstacle in overcoming breast cancer recurrence and metastasis. It is known that mitochondria play an important role in carcinoma cell growth, invasion and apoptosis. Recent studies have explored the involvement of mitochondrial metabolism in breast cancer prognosis. Here, we will provide an overview of studies that investigated mitochondrial metabolism pathways in breast cancer treatment resistance, and discuss the application prospects of agents targeting mitochondrial pathways against drug-resistant breast cancer.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Zhichao Wang, Shanghai Jiao Tong University, China; Wenjuan Wang, Children’s Hospital of Soochow University, China
Edited by: Zheng Wang, Shanghai Jiao Tong University, China
This article was submitted to Women’s Cancer, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.629614